In particular, the introduction of Cyclin-Dependent Kinase 4/6 (CDK 4/6) inhibitors and PIK3CA/mTORC1 inhibitors in combination with endocrine treatments contributed to significantly prolong disease control in patients with advanced hormone receptor-positive (HR+) BC, while the PD-L1 inhibitor atezolizumab in combination with nab-paclitaxel recently improved the progression-free survival (PFS) of patients with advanced triple-negative breast cancer (TNBC) in the first-line setting [2,3,4,5,6,7]. The gene discussed is NR4A1; the disease is breast cancer.